A review of targeted therapies for anemia in patients with lower-risk myelodysplastic syndromes and myelofibrosis that improve transfusion independence and hemoglobin levels.

Researchers sought to determine whether patients with T-ALL would be responsive to salvage therapy with homoharringtonine, cytarabine, and aclarubicin.

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Higher weighted years with overweight/obesity linked to increased risk for overall, aggressive, fatal, and clear-cell renal cell carcinoma.

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...